Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Daniel Prieto-Alhambra"'
Autor:
V. Hughes, Andrea Dell'Isola, Aleksandra Turkiewicz, Weiya Zhang, Sita M A Bierma-Zeinstra, Martin Englund, Kenneth Pihl, Daniel Prieto-Alhambra
Publikováno v:
Arthritis Care and Research, 74(10), 1689-1695. John Wiley & Sons Inc.
Objective To estimate the risk of developing comorbidities in patients after physician-diagnosed knee or hip osteoarthritis (OA). Methods This was a cohort study using Swedish longitudinal health care register data; we studied residents in the Skåne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::810e9cbfad0a01c4ef539a75e2cbab7a
https://pure.eur.nl/en/publications/25015d33-aaa4-4bd1-acfd-12b9ef29ff2a
https://pure.eur.nl/en/publications/25015d33-aaa4-4bd1-acfd-12b9ef29ff2a
Autor:
S Khalid, Cesar Libanati, Carlen Reyes, Bo Abrahamsen, Martin Ernst, Daniel Prieto-Alhambra, Antonella Delmestri, E Toth
Publikováno v:
Khalid, S, Reyes, C, Ernst, M, Delmestri, A, Toth, E, Libanati, C, Abrahamsen, B & Prieto-Alhambra, D 2022, ' One-and 2-year incidence of osteoporotic fracture : a multi-cohort observational study using routinely collected real-world data ', Osteoporosis International, vol. 33, no. 1, pp. 123-137 . https://doi.org/10.1007/s00198-021-06077-0
Osteoporosis International
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Osteoporosis International
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Summary We estimated and characterized the imminent fracture risk (1–2 years) of high-risk fracture patients through a multinational (UK, Spain, Denmark) cohort study. Older individuals with newly diagnosed osteoporosis and individuals who had a fr
Autor:
John A. Kanis, Nicholas C Harvey, F. Tremollieres, Nasser M. Al-Daghri, Thierry Thomas, Olivier Bruyère, Daniel Prieto-Alhambra, René Rizzoli, Adolfo Diez-Perez, Elaine M. Dennison, Cyrus Cooper, Nicholas R Fuggle, Antonio Cano, Serge Rozenberg, Santiago Palacios, Jean-Marc Kaufman, M. L. Brandi, Jean-Yves Reginster
Publikováno v:
Drugs
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
DRUGS
Drugs, Vol. 80, No 15 (2020) pp. 1537-1552
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
DRUGS
Drugs, Vol. 80, No 15 (2020) pp. 1537-1552
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
The incidence of osteoporosis and cardiovascular disease increases with age, and there are potentially shared mechanistic associations between the two conditions. It is therefore highly relevant to understand the cardiovascular implications of osteop
Publikováno v:
Current Opinion in Rheumatology. 32:387-393
Purpose of review The field of osteoporosis research has been active for the past 20 years and has allowed significant advancement in the management of osteoporosis. This review will give an overview of the latest data from international cohorts that
Autor:
Ricardo, Larrainzar-Garijo, Adolfo, Díez-Pérez, Esther, Fernández-Tormos, Daniel, Prieto-Alhambra
Publikováno v:
Archives of orthopaedic and trauma surgery. 142(10)
The risk factors for a second nonsimultaneous hip fracture are unclear, and in general, it is empirically assumed that they are similar to those associated with the first hip fracture. We aimed to determine the incidence of a second hip fracture and
Autor:
Nicholas C Harvey, Kazem Rahimi, Dexter Canoy, Haakon E. Meyer, Milad Nazarzadeh, Cyrus Cooper, Bjørn Olav Åsvold, Daniel Prieto-Alhambra
Publikováno v:
Osteoporosis International
Osteoporosis International, 33(2), 315-326. Springer London
Osteoporosis International, 33(2), 315-326. Springer London
Blood pressure and bone metabolism appear to share commonalities in their physiologic regulation. Specific antihypertensive drug classes may also influence bone mineral density. However, current evidence from existing observational studies and random
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7fe7232ec471470b75c974f146d9c78
https://hdl.handle.net/11250/3009434
https://hdl.handle.net/11250/3009434
Autor:
Fergus Caskey, Danielle E Robinson, Victoria Y Strauss, Daniel Dedman, María José Pérez-Sáez, Daniel Prieto-Alhambra, Natalia Pallares, Xavier Nogués, Bo Abrahamsen, Antonella Delmestri, Leena Elhussein, Cristian Tebé, Adolfo Diez-Perez, Andrew Judge, Nigel K Arden, Yoav Ben-Shlomo, Julio Pascual, Cyrus Cooper, M Sanni Ali, M Kassim Javaid
Publikováno v:
Robinson, D E, Ali, M S, Pallares, N, Tebé, C, Ben-Shlomo, Y, Caskey, F J, Judge, A, Prieto-Alhambra, D & al., E 2020, ' Safety of oral bisphosphonates in moderate-to-severe chronic kidney disease : a bi-national cohort analysis ', Journal of Bone and Mineral Research . https://doi.org/10.1002/jbmr.4235
Robinson, D E, Ali, M S, Pallares, N, Tebé, C, Elhussein, L, Abrahamsen, B, Arden, N K, Ben-Shlomo, Y, Caskey, F J, Cooper, C, Dedman, D, Delmestri, A, Judge, A, Pérez-Sáez, M J, Pascual, J, Nogues, X, Diez-Perez, A, Strauss, V Y, Javaid, M K & Prieto-Alhambra, D 2021, ' Safety of Oral Bisphosphonates in Moderate-to-Severe Chronic Kidney Disease : A Binational Cohort Analysis ', Journal of Bone and Mineral Research, vol. 36, no. 5, pp. 820-832 . https://doi.org/10.1002/jbmr.4235
Robinson, D E, Ali, M S, Pallares, N, Tebé, C, Elhussein, L, Abrahamsen, B, Arden, N K, Ben-Shlomo, Y, Caskey, F J, Cooper, C, Dedman, D, Delmestri, A, Judge, A, Pérez-Sáez, M J, Pascual, J, Nogues, X, Diez-Perez, A, Strauss, V Y, Javaid, M K & Prieto-Alhambra, D 2021, ' Safety of Oral Bisphosphonates in Moderate-to-Severe Chronic Kidney Disease : A Binational Cohort Analysis ', Journal of Bone and Mineral Research, vol. 36, no. 5, pp. 820-832 . https://doi.org/10.1002/jbmr.4235
Bisphosphonates are the first-line treatment for preventing fractures in osteoporosis patients. However, their use is contraindicated or to be used with caution in chronic kidney disease (CKD) patients, primarily because of a lack of information abou
Autor:
Daniel Prieto-Alhambra, Bo Abrahamsen, Alexander J. Rodríguez, Anne Pernille Hermann, Peter R. Ebeling, Martin Ernst, Mads Nybo
Publikováno v:
Rodriguez, A J, Ernst, M T, Nybo, M, Prieto-Alhambra, D, Ebeling, P R, Hermann, A P & Abrahamsen, B 2020, ' Oral bisphosphonate use reduces cardiovascular events in a cohort of Danish patients referred for bone mineral density ', The Journal of clinical endocrinology and metabolism, vol. 105, no. 10, dgaa481, pp. 3215-3225 . https://doi.org/10.1210/clinem/dgaa481
Context The cardiovascular (CV) safety of oral bisphosphonates (oBPs) is uncertain. Objective Determine the risk of CV events in oBP users referred for bone mineral density (BMD) testing compared with matched controls. Design Cohort study. Setting Da
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::517fd9c06f8ee1ebd9414dc61edd99f9
https://doi.org/10.1210/clinem/dgaa481
https://doi.org/10.1210/clinem/dgaa481
Autor:
Daniel Prieto-Alhambra, Danielle E Robinson, Yoav Ben-Shlomo, Fergus Caskey, Mads Nybo, M Sanni Ali, Cyrus Cooper, Muhammad Javaid, Martin Thomsen Ernst, Katrine Hass Rubin, Anne Pernille Hermann, Nigel K Arden, Andrew Judge
Publikováno v:
Archives of Osteoporosis
Ali, M S, Ernst, M, Robinson, D E, Caskey, F, Arden, N K, Ben-Shlomo, Y, Nybo, M, Rubin, K H, Judge, A, Cooper, C, Javaid, M K, Hermann, A P & Prieto-Alhambra, D 2020, ' Alendronate use and bone mineral density gains in women with moderate-severe (stages 3B-5) chronic kidney disease : an open cohort multivariable and propensity score analysis from Funen, Denmark ', Archives of Osteoporosis, vol. 15, no. 1, 81 . https://doi.org/10.1007/s11657-020-00746-z
Ali, M S, Ernst, M, Robinson, D E, Caskey, F, Arden, N K, Ben-Shlomo, Y, Nybo, M, Rubin, K H, Judge, A, Cooper, C, Javaid, M K, Hermann, A P & Prieto-Alhambra, D 2020, ' Alendronate use and bone mineral density gains in women with moderate-severe (stages 3B-5) chronic kidney disease : an open cohort multivariable and propensity score analysis from Funen, Denmark ', Archives of Osteoporosis, vol. 15, no. 1, 81 (2020) . https://doi.org/10.1007/s11657-020-00746-z
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Ali, M S, Ernst, M, Robinson, D E, Caskey, F, Arden, N K, Ben-Shlomo, Y, Nybo, M, Rubin, K H, Judge, A, Cooper, C, Javaid, M K, Hermann, A P & Prieto-Alhambra, D 2020, ' Alendronate use and bone mineral density gains in women with moderate-severe (stages 3B-5) chronic kidney disease : an open cohort multivariable and propensity score analysis from Funen, Denmark ', Archives of Osteoporosis, vol. 15, no. 1, 81 . https://doi.org/10.1007/s11657-020-00746-z
Ali, M S, Ernst, M, Robinson, D E, Caskey, F, Arden, N K, Ben-Shlomo, Y, Nybo, M, Rubin, K H, Judge, A, Cooper, C, Javaid, M K, Hermann, A P & Prieto-Alhambra, D 2020, ' Alendronate use and bone mineral density gains in women with moderate-severe (stages 3B-5) chronic kidney disease : an open cohort multivariable and propensity score analysis from Funen, Denmark ', Archives of Osteoporosis, vol. 15, no. 1, 81 (2020) . https://doi.org/10.1007/s11657-020-00746-z
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Summary Bisphosphonates are contraindicated in moderate-to-severe chronic kidney disease patients. However, they are used to prevent fragility fractures in patients with impaired kidney function, despite a lack of evidence on their effects on bone de
Autor:
Daniel Prieto-Alhambra, Antonio Cano, F. Tremollieres, René Rizzoli, Andrea Laslop, M. L. Brandi, Nasser M. Al-Daghri, T. Hillard, Jean-Yves Reginster, J. A. Kanis, Cyrus Cooper, JM Kaufman, Nicholas C. Harvey, Peter Collins, Serge Rozenberg, Andrea Ricardo Genazzani, Eugene V. McCloskey, Mylène Aubertin-Leheudre, G. Rosano, Santiago Palacios, Irene Lambrinoudaki
Publikováno v:
OSTEOPOROSIS INTERNATIONAL
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Osteoporosis International
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Osteoporosis International
We provide an evidence base and guidance for the use of menopausal hormone therapy (MHT) for the maintenance of skeletal health and prevention of future fractures in recently menopausal women. Despite controversy over associated side effects, which h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55240f580792d723fad623795e2bd966
https://biblio.ugent.be/publication/8698874/file/8698950
https://biblio.ugent.be/publication/8698874/file/8698950